INDIANAPOLIS, Nov. 18, 2021 /PRNewswire/ -- Today, Eli
Lilly and Company (NYSE: LLY) announced that enrollment is now open
for the CHALLENGE-MIG clinical trial, the first and only
head-to-head trial comparing two anti-calcitonin gene-related
peptide (CGRP) medicines for the preventive treatment of episodic
migraine in adults.1 The study is evaluating
once-monthly Emgality® (galcanezumab-gnlm) injection compared to
Nurtec® ODT (rimegepant), a tablet patients take every other day,
on patient-centric measures, including reductions in monthly
migraine headache days and quality of life improvement.
While Nurtec ODT and Emgality are both medications that target
CGRP, because Emgality is a monoclonal antibody (mAb) that
binds to CGRP (a protein found in the brain thought to play a key
role in migraine), it works differently than gepants like Nurtec
ODT, that bind to and block the CGRP
receptor.2-4 Emgality is the only CGRP medication
with ≥50%, ≥75% and 100% reductions of monthly migraine headache
days in its label for people with episodic migraine experiencing 4
to 14 migraine headache days per month. Lilly's CHALLENGE-MIG study
aims to deepen the understanding of CGRP monoclonal antibodies
(mAbs) compared to oral gepants in the preventive treatment of
migraine and answer important questions that will help physicians
and patients make informed treatment decisions.
"Migraine can greatly impact day-to-day activities, robbing
people of their routines and their everyday and special occasions
in life. Reducing the frequency of migraine attacks can help people
achieve more migraine-free days and enjoy an improved quality of
life; both of which are essential treatment goals," said
Shivang Joshi, a trial investigator
and neurologist at Dent Neurologic Institute. "Lilly's
CHALLENGE-MIG study will help us understand how different types of
preventive medications (CGRP mAbs vs. gepants) may help people
achieve the goals that matter most to them. It's exciting that
insights generated in this first-of-its-kind head-to-head trial
will be able to spark treatment plan discussions between people
with migraine and their health care providers."
The CHALLENGE-MIG clinical trial is expected to enroll
approximately 700 adults across the U.S. with episodic migraine,
and individual participation in the study can last up to 6 months.
For more information about the CHALLENGE-MIG trial, contact The
Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). Information
about the CHALLENGE-MIG study is also available at the Lilly booth
at the American Headache Society's annual education symposium
taking place in Scottsdale, AZ,
November 18-21, 2021.
"Lilly has been deeply committed to neuroscience research across
a spectrum of diseases for over 30 years," said Anne White, senior vice president of Eli Lilly
and Company and president of Lilly Neuroscience. "We believe
patients should expect more and get more from medications that can
help prevent migraine. Therefore, we look forward to sharing the
findings from our Emgality versus Nurtec ODT head-to-head
trial."
About the CHALLENGE-MIG Study
In the first
head-to-head clinical trial comparing two medications targeting
calcitonin gene-related peptide (CGRP), the CHALLENGE-MIG is a
randomized, double-blind, placebo-controlled Phase 4 study in adult
patients who meet the International Classification of Headache
Disorders-3 (ICHD-3) criteria for a diagnosis of migraine with or
without aura and experiencing 4-14 migraine headache days per
month. The study aims to evaluate the efficacy and safety of
once-monthly injectable Emgality®
(galcanezumab-gnlm) compared to every-other-day
Nurtec® ODT (rimegepant) taken orally. The primary
endpoint is ≥50% reduction from baseline in monthly migraine
headache days across the 3-month double-blind treatment period.
Secondary endpoints include ≥75% and 100% reduction from baseline
in monthly migraine headache days and improvements in the
Migraine-Specific Quality of Life (MSQ), a 14-item questionnaire
designed to measure migraine-specific health-related quality of
life by assessing the limitation of daily performance, and the
Migraine Disability Assessment (MIDAS), a five-item questionnaire
used to assess headache-related disability in the past three
months.
About Emgality
Emgality is a monoclonal antibody that selectively binds to
calcitonin gene-related peptide (CGRP) and was approved by the FDA
in September 2018 for the preventive treatment of migraine in
adults. Emgality is the only CGRP monoclonal antibody with response
rates in the episodic migraine headache population on ≥50%, ≥75%
and 100% reduction from baseline in monthly migraine headache days
over Months 1 to 6 included in its Full Prescribing Information.
In June 2019, Emgality was approved by the FDA for the
treatment of episodic cluster headache in adults.
Indications and Usage for Emgality (galcanezumab-gnlm) 120 mg
Injection
Emgality is a calcitonin gene-related peptide
(CGRP) antagonist indicated in adults for the:
- preventive treatment of migraine
- treatment of episodic cluster headache
Important Safety Information for Emgality
Contraindications
Emgality is contraindicated in
patients with serious hypersensitivity to galcanezumab-gnlm or to
any of the excipients.
Warnings and Precautions
Hypersensitivity Reactions
Hypersensitivity reactions,
including dyspnea, urticaria, and rash, have occurred with Emgality
in clinical studies and the postmarketing setting. Cases of
anaphylaxis and angioedema have also been reported in the
postmarketing setting. If a serious or severe hypersensitivity
reaction occurs, discontinue administration of Emgality and
initiate appropriate therapy. Hypersensitivity reactions can occur
days after administration and may be prolonged.
Adverse Reactions
The most common adverse reactions
(incidence ≥2% and at least 2% greater than placebo) in Emgality
clinical studies were injection site reactions.
Please see Full Prescribing Information,
including Patient Information, for Emgality. See
Instructions for Use included with the device.
GZ HCP ISI 10DEC2019
About Migraine
Migraine is a severely disabling
neurologic disease characterized by recurrent episodes of moderate
to severe headache accompanied by other symptoms including nausea,
sensitivity to light, and sensitivity to sound.5,6 More
than 30 million American adults have migraine, with three times
more women than men affected by migraine.7 Migraine is
often incapacitating, leading to high personal, societal and
economic burden. According to the Medical Expenditures Panel
Survey, total annual healthcare costs associated with migraine are
estimated to be as high as $56
billion in the United
States, yet it remains under-recognized and
under-treated.8
About Lilly's Commitment to Headache Disorders
For more than 25 years, Lilly has been committed to helping people
affected by headache disorders, investigating more than a dozen
different compounds for the treatment of migraine and cluster
headache. These research programs have accelerated our
understanding of these diseases and furthered the advancement of
treatments for headache disorders. Our goal is to apply our
combined clinical, academic and professional experience to build a
research portfolio that delivers broad solutions and addresses the
needs of people affected by these disabling neurologic
diseases.
About Eli Lilly and Company
Lilly is a global health
care leader that unites caring with discovery to create medicines
that make life better for people around the world. We were founded
more than a century ago by a man committed to creating high-quality
medicines that meet real needs, and today we remain true to that
mission in all our work. Across the globe, Lilly employees work to
discover and bring life-changing medicines to those who need them,
improve the understanding and management of disease, and give back
to communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at lilly.com and
lilly.com/newsroom.
Lilly Forward-Looking Statement
This press release
contains forward-looking statements (as that term is defined in the
Private Securities Litigation Reform Act of 1995) about Emgality
(galcanezumab-gnlm) as a preventive treatment for patients with
migraine and as a treatment for patients with episodic cluster
headache, and reflects Lilly's current beliefs and expectations.
However, as with any pharmaceutical product, there are substantial
risks and uncertainties in the process of drug research,
development, and commercialization. Among other things, there is no
guarantee that planned or ongoing studies will be completed as
planned, that future study results will be consistent with
study findings to date, that Emgality will receive any additional
regulatory approvals, or that Emgality will be commercially
successful. For further discussion of these and other risks and
uncertainties, see Lilly's most recent Form 10-K and Form 10-Q
filings with the United States Securities and Exchange Commission.
Except as required by law, Lilly undertakes no duty to update
forward-looking statements to reflect events after the date of this
release.
P-LLY
All product/company names shown herein are the trademarks of
their respective owners.
References:
- A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study
Evaluating the Efficacy and Safety of Galcanezumab Versus
Rimegepant in Adult Participants with Episodic Migraine.
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Russo AF. Calcitonin gene-related peptide (CGRP): a new target
for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552.
- Garza I, Swanson JW. Prophylaxis of migraine. Neuropsychiatr
Dis Treat. 2006;2(3):281-291.
- Katsarava Z, Buse D, Manack A, et al. Defining the differences
between episodic migraine and chronic migraine. Current Pain
Headache Reports. 2012;16:86.
- Blumenfeld AM, Payne KA, Varon SF, et al. Disability, HRQOL,
and resource use amongst chronic and episodic migraineurs. Results
from the International Burden of Migraine Study (IBMS).
Cephalalgia. 2011;31:301.
- Lipton RB, Bigal ME, Diamond M, et al., Migraine prevalence,
disease burden, and the need for preventive therapy. Neurology.
2007;68:343-349.
- Raval AD, Shah A. National trends in direct health care
expenditures among U.S. adults with migraine: 2004 to 2013. Journal
of Pain. 2017;57:60.
Refer
to:
|
Marlo Scott;
scott_marlo@lilly.com; 317-407-8879 (Lilly
Communications)
|
|
Kevin
Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investor
Relations)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/emgality-versus-nurtec-odt-head-to-head-migraine-preventive-treatment-study-now-enrolling-patients-301427983.html
SOURCE Eli Lilly and Company